Diakine-DK210 (EGFR) is under clinical development by Deka Biosciences and currently in Phase I for Skin Cancer. According to GlobalData, Phase I drugs for Skin Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Diakine-DK210 (EGFR)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diakine-DK210 (EGFR) overview

Diakine-DK210 (EGFR) is under development for the treatment of solid tumors including kidney cancer (Renal Cell Cancer), skin cancer, non-small cell lung cancer, bladder cancer, pancreatic cancer, colorectal cancer, head and neck cancer and solid tumor. It s being administered through subcutaneous route. The therapeutic candidate comprises of coupled interleukin-2 and interleukin-10 variants that acts by targeting EGFR. Drug candidate is being developed based on Diakine platform.

Deka Biosciences overview

Deka Biosciences is a pharmaceutical company which is developing next generation targeted cytokine therapies to treat cancer and inflammatory diseases. The company is headquartered in Germantown, Maryland, the US.

For a complete picture of Diakine-DK210 (EGFR)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.